Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Author:
Funder
Regeneron Pharmaceuticals
Sanofi
Publisher
Elsevier BV
Subject
Dermatology
Reference5 articles.
1. Guidelines of care for the management of atopic dermatitis: section 4. Prevention of disease flares and use of adjunctive therapies and approaches;Sidbury;J Am Acad Dermatol,2014
2. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients;Wollenberg;J Eur Acad Dermatol Venereol,2016
3. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I;Wollenberg;J Eur Acad Dermatol Venereol,2018
4. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II;Wollenberg;J Eur Acad Dermatol Venereol,2018
5. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial;Blauvelt;Lancet,2017
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment;Dermatology and Therapy;2024-08
2. A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis;Journal of Clinical Medicine;2024-07-09
3. Early Dupilumab Response Predicts Pediatric Atopic Dermatitis Disease Relapse;Dermatitis®;2024-07-01
4. Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155–1166;Journal of Medical Economics;2024-06-10
5. Dupilumab and Atopic Dermatitis Flares: An Observational Study to Identify Common Clinical Features in Patients Who Have Exacerbations Despite Biological Therapy;Dermatitis®;2024-02-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3